PF-04885614 is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It has shown promise as an inhibitor targeting specific pathways involved in cancer cell proliferation and survival. Researchers are exploring its efficacy in preclinical studies to determine its ability to suppress tumor growth and enhance the effectiveness of existing cancer treatments. Additionally, its role in modulating cellular mechanisms makes it a candidate for combination therapies, potentially reducing resistance to conventional treatments. Further studies are ongoing to evaluate its safety, pharmacokinetics, and potential for clinical use in cancer patients.